Aldeyra Therapeutics, Inc.ALDX
時価総額
$3億
PER
眼科・免疫疾患向け医薬品の新興企業。従業員9名体制で外部委託を活用しreproxalapなどの候補薬の臨床開発と商業準備を展開。2019年1月の他社買収と2024年の買収候補薬開発中止。米国中心に展開。
| 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | 2024年 12月31日 | |
| Cash and cash equivalents | - | - | - | - | 3 | 16 | 53 | 105 | 144 | 143 | 55 |
| Cash Equivalent Reverse Repurchase Agreement | - | - | - | - | 44 | 28 | 25 | 125 | - | - | - |
| Marketable securities | - | - | - | - | - | 29 | - | - | 30 | - | 47 |
| Prepaid expenses and other current assets | 232,568 | 497,552 | 218,682 | 1 | 1 | 2 | 5 | 3 | 7 | 5 | 3 |
| Total current assets | 9 | 28 | 25 | 44 | 95 | 75 | 83 | 233 | 181 | 148 | 104 |
| Deferred offering costs | - | - | - | - | - | - | - | - | - | - | 267,261 |
| Fixed assets, net | 12,993 | 80,334 | 56,352 | 43,262 | 235,225 | 148,449 | 59,925 | 32,487 | 19,279 | 5,764 | - |
| Right-of-use assets | - | - | - | - | - | 201,007 | 233,310 | 351,863 | 249,265 | 1 | 266,955 |
| Total assets | 9 | 28 | 25 | 44 | 95 | 76 | 83 | 233 | 181 | 148 | 105 |
| Accounts payable | 341,294 | 851,160 | 275,441 | 1 | 3 | 808,302 | 381,638 | 1 | 133,625 | 1 | 180,453 |
| Accrued expenses | 908,724 | 1 | 2 | 2 | 5 | 12 | 8 | 11 | 14 | 6 | 12 |
| Current portion of debt | 77,546 | 77,546 | 77,546 | 116,319 | - | - | - | - | 911,763 | 15 | 31,372 |
| Operating lease liabilities | - | - | - | - | - | 226,328 | 233,310 | 229,607 | 249,265 | 239,183 | 271,631 |
| Deferred Revenue, Current | - | - | - | - | - | - | - | - | - | - | 6 |
| Total current liabilities | 1 | 2 | 2 | 3 | 8 | 13 | 12 | 12 | 15 | 22 | 19 |
| Deferred Long-Term Liability Charges | - | - | - | - | - | - | - | - | - | 6 | - |
| Operating lease liabilities, long-term | - | - | - | - | - | - | - | 125,232 | - | 271,631 | - |
| Long-term debt, net of current portion | 1 | 1 | 1 | 1 | - | 15 | 11 | 16 | 15 | - | 15 |
| Total liabilities | 3 | 3 | 4 | 5 | 8 | 27 | 24 | 27 | 30 | 29 | 34 |
| Common Stock, Value, Issued | - | 9,713 | 12,576 | 19,138 | 26,244 | 28,657 | 38,667 | 58,081 | 58,560 | 59,196 | 59,648 |
| Additional paid-in capital | 53 | 83 | 99 | 139 | 225 | 247 | 296 | 500 | 508 | 514 | 521 |
| Accumulated other comprehensive income | - | -8,361 | 129 | -17,831 | -9,224 | 5,866 | - | - | -103,938 | - | 37,442 |
| Accumulated deficit | -46,511,597 | -58,601,884 | -77,301,334 | -99,641,923 | -138,535,168 | -199,361,999 | -236,915,728 | -294,692,002 | -356,716,638 | -394,259,148 | -450,110,592 |
| Total stockholders’ equity | 6 | 25 | 22 | 40 | 87 | 48 | 60 | 206 | 151 | 120 | 71 |
| Total liabilities and stockholders’ equity | 9 | 28 | 25 | 44 | 95 | 76 | 83 | 233 | 181 | 148 | 105 |